Company performance
Current Price
as of Jan 10, 2025$52.80
P/E Ratio
17.47
Market Cap
$6.72B
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerHALO
- Price$52.8-1.79%
Trading Information
- Market cap$6.72B
- Float98.95%
- Average Daily Volume (1m)1,655,828
- Average Daily Volume (3m)1,660,321
- EPS$3.08
Company
- Revenue$947.35M
- Rev growth (1yr)34.28%
- Net income$137.01M
- Gross margin76.84%
- EBITDA margin63.28%
- EBITDA$183.56M
- EV$8.29B
- EV/Revenue8.75
- P/E17.47
- P/S7.25
- P/B14.83
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia